Cargando…

SMARCB1 expression is a novel diagnostic and prognostic biomarker for osteosarcoma

Background: Although weak SWI/SNF related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 (SMARCB1) expression is a known diagnostic and prognostic biomarker in several malignancies, its expression and clinical significance in osteosarcoma remain unknown. The aim of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Tao, Wei, Ran, Dean, Dylan C., Hornicek, Francis J., Duan, Zhenfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753343/
https://www.ncbi.nlm.nih.gov/pubmed/34984436
http://dx.doi.org/10.1042/BSR20212446
_version_ 1784632076296781824
author Guo, Tao
Wei, Ran
Dean, Dylan C.
Hornicek, Francis J.
Duan, Zhenfeng
author_facet Guo, Tao
Wei, Ran
Dean, Dylan C.
Hornicek, Francis J.
Duan, Zhenfeng
author_sort Guo, Tao
collection PubMed
description Background: Although weak SWI/SNF related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 (SMARCB1) expression is a known diagnostic and prognostic biomarker in several malignancies, its expression and clinical significance in osteosarcoma remain unknown. The aim of the present study was to investigate SMARCB1 expression in osteosarcoma and its clinical significance with respect to chemosensitivity and prognosis. Methods: We obtained 114 specimens from 70 osteosarcoma patients to construct a tissue microarray (TMA) and assess SMARCB1 protein expression via immunohistochemistry (IHC). The mRNA expression of SMARCB1 was in-silico analyzed using open-access RNA sequencing (RNA-Seq) and clinicopathological data provided by the Therapeutically Applicable Research to Generate Effective Treatments on Osteosarcoma (TARGET-OS) project. The correlations between SMARCB1 expression and clinical features were statistically analyzed. Results: Weak SMARCB1 expression occurred in 70% of the osteosarcoma patient specimens in the TMA, and significantly correlated with poor neoadjuvant response as well as shorter overall and progression-free survival (PFS). In addition, mRNA in-silico analysis confirmed that SMARCB1 expression correlates with chemotherapeutic response and prognosis in osteosarcoma patients. Conclusion: To our knowledge, the present study is the first to analyze SMARCB1 expression in osteosarcoma. SMARCB1 may serve as a novel diagnostic and prognostic biomarker in osteosarcoma.
format Online
Article
Text
id pubmed-8753343
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Portland Press Ltd.
record_format MEDLINE/PubMed
spelling pubmed-87533432022-01-25 SMARCB1 expression is a novel diagnostic and prognostic biomarker for osteosarcoma Guo, Tao Wei, Ran Dean, Dylan C. Hornicek, Francis J. Duan, Zhenfeng Biosci Rep Cancer Background: Although weak SWI/SNF related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 (SMARCB1) expression is a known diagnostic and prognostic biomarker in several malignancies, its expression and clinical significance in osteosarcoma remain unknown. The aim of the present study was to investigate SMARCB1 expression in osteosarcoma and its clinical significance with respect to chemosensitivity and prognosis. Methods: We obtained 114 specimens from 70 osteosarcoma patients to construct a tissue microarray (TMA) and assess SMARCB1 protein expression via immunohistochemistry (IHC). The mRNA expression of SMARCB1 was in-silico analyzed using open-access RNA sequencing (RNA-Seq) and clinicopathological data provided by the Therapeutically Applicable Research to Generate Effective Treatments on Osteosarcoma (TARGET-OS) project. The correlations between SMARCB1 expression and clinical features were statistically analyzed. Results: Weak SMARCB1 expression occurred in 70% of the osteosarcoma patient specimens in the TMA, and significantly correlated with poor neoadjuvant response as well as shorter overall and progression-free survival (PFS). In addition, mRNA in-silico analysis confirmed that SMARCB1 expression correlates with chemotherapeutic response and prognosis in osteosarcoma patients. Conclusion: To our knowledge, the present study is the first to analyze SMARCB1 expression in osteosarcoma. SMARCB1 may serve as a novel diagnostic and prognostic biomarker in osteosarcoma. Portland Press Ltd. 2022-01-11 /pmc/articles/PMC8753343/ /pubmed/34984436 http://dx.doi.org/10.1042/BSR20212446 Text en © 2022 The Author(s). https://creativecommons.org/licenses/by/4.0/This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY) (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Cancer
Guo, Tao
Wei, Ran
Dean, Dylan C.
Hornicek, Francis J.
Duan, Zhenfeng
SMARCB1 expression is a novel diagnostic and prognostic biomarker for osteosarcoma
title SMARCB1 expression is a novel diagnostic and prognostic biomarker for osteosarcoma
title_full SMARCB1 expression is a novel diagnostic and prognostic biomarker for osteosarcoma
title_fullStr SMARCB1 expression is a novel diagnostic and prognostic biomarker for osteosarcoma
title_full_unstemmed SMARCB1 expression is a novel diagnostic and prognostic biomarker for osteosarcoma
title_short SMARCB1 expression is a novel diagnostic and prognostic biomarker for osteosarcoma
title_sort smarcb1 expression is a novel diagnostic and prognostic biomarker for osteosarcoma
topic Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753343/
https://www.ncbi.nlm.nih.gov/pubmed/34984436
http://dx.doi.org/10.1042/BSR20212446
work_keys_str_mv AT guotao smarcb1expressionisanoveldiagnosticandprognosticbiomarkerforosteosarcoma
AT weiran smarcb1expressionisanoveldiagnosticandprognosticbiomarkerforosteosarcoma
AT deandylanc smarcb1expressionisanoveldiagnosticandprognosticbiomarkerforosteosarcoma
AT hornicekfrancisj smarcb1expressionisanoveldiagnosticandprognosticbiomarkerforosteosarcoma
AT duanzhenfeng smarcb1expressionisanoveldiagnosticandprognosticbiomarkerforosteosarcoma